CD274 and Hodgkins lymphoma: In fact, HL patients frequently carry 9p24.1 amplification, with associated PD-1 ligand overexpression and concurrent gains in the PDL1 and PDL2 loci, supporting the use of an anti-PD1 blockade in this disease [37].